{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:24:06Z","timestamp":1789079046843,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.medj.2024.10.019","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T10:36:54Z","timestamp":1734086214000},"page":"1446-1448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel agents for treating severe hypertriglyceridemia"],"prefix":"10.1016","volume":"5","author":[{"given":"Anthony S.","family":"Wierzbicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.10.019_bib1","article-title":"Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk","author":"Watts","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2024.10.019_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","author":"Ginsberg","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.medj.2024.10.019_bib3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/metabo13050621","article-title":"Severe Hypertriglyceridaemia and Chylomicronaemia Syndrome-Causes, Clinical Presentation, and Therapeutic Options","volume":"13","author":"Bashir","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.medj.2024.10.019_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12933-024-02305-z","article-title":"Lessons from PROMINENT and prospects for pemafibrate","volume":"23","author":"Fruchart","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.medj.2024.10.019_bib5","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.10.019_bib6","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.10.019_bib7","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2147\/DDDT.S224771","article-title":"Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy","volume":"14","author":"Esan","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.medj.2024.10.019_bib8","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.10.019_bib9","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.10.019_bib10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024004173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024004173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T03:08:51Z","timestamp":1765595331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024004173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2666634024004173"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.10.019","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel agents for treating severe hypertriglyceridemia","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}